Human Immunodeficiency Virus Therapeutics Global Market Report 2025

Description

Human immunodeficiency virus (HIV) therapeutics refer to treatments and medications aimed at managing and suppressing HIV infection, primarily through antiretroviral therapy (ART). These therapies work to lower the viral load, prevent the progression to AIDS, and enhance the quality of life for people living with HIV.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary drug types in HIV therapeutics include branded and generic drugs. Branded drugs are patented treatments developed and marketed under specific trade names after extensive research and clinical evaluation to ensure efficacy and safety. The major drug classes encompass nucleoside-analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry and fusion inhibitors, protease inhibitors (PIs), integrase inhibitors, and coreceptor antagonists. These medications are distributed via hospital pharmacies, online platforms, and retail pharmacies and are utilized by end users such as hospitals, clinics, and specialty treatment centers.

The human immunodeficiency virus therapeutics market research report is one of a series of new reports from The Business Research Company that provides human immunodeficiency virus therapeutics market statistics, including the human immunodeficiency virus therapeutics industry global market size, regional shares, competitors with the human immunodeficiency virus therapeutics market share, detailed human immunodeficiency virus therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the human immunodeficiency virus therapeutics industry. This human immunodeficiency virus therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The human immunodeficiency virus therapeutics market size has grown strongly in recent years. It will grow from$14.11 billion in 2024 to $14.94 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to the increasing prevalence of HIV, expansion of awareness initiatives, a rise in diagnostic testing, greater penetration of generic drugs, and the development of healthcare infrastructure.

The human immunodeficiency virus therapeutics market size is expected to see strong growth in the next few years. It will grow to$18.57 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth during the forecast period can be attributed to an increasing HIV patient population, a rise in HIV screening efforts, growth in voluntary testing rates, a surge in unprotected sexual practices, and the expansion of government-led programs. Major trends in the forecast period include advancements in technology, AI-driven drug development, the emergence of long-acting injectable treatments, the integration of telemedicine, and the exploration of CRISPR-based gene therapies.

The rising incidence of unprotected sexual activity is a key factor propelling the growth of the human immunodeficiency virus (HIV) therapeutics market. Unprotected sex-defined as sexual activity without the use of barrier protection-significantly elevates the risk of sexually transmitted infections (STIs), including HIV. This trend is exacerbated by limited access to contraceptive methods and the absence of comprehensive sex education, particularly among adolescents and young adults. HIV therapeutics play a critical role in suppressing viral load, thereby preventing transmission and improving patient outcomes. For example, according to a November 2024 report from the Centers for Disease Control and Prevention (CDC), 32% of U.S. high school students surveyed in 2023 reported having had sexual intercourse, and 48% did not use a condom during their most recent encounter. These statistics highlight the urgent need for effective HIV interventions and support the growing demand for antiretroviral therapies.

Leading companies in the HIV therapeutics market are advancing combination therapy strategies to improve efficacy, minimize drug resistance, and promote patient adherence. Combination therapy involves using two or more drugs simultaneously to treat HIV, offering several benefits such as improved virologic control, reduced pill burden, and lower risk of resistance development. In December 2022, Gilead Sciences Inc., a U.S.-based biopharmaceutical firm, received FDA approval for Sunlenca (lenacapavir), a novel long-acting capsid inhibitor. Approved for use in combination with other antiretroviral agents, Sunlenca is intended for adults with multidrug-resistant HIV-1. It is the first HIV medication in its class and offers a biannual dosing regimen, which significantly enhances convenience and adherence. The approval was supported by the CAPELLA trial, which demonstrated strong and sustained virologic suppression. Innovations such as Sunlenca are reshaping the treatment landscape, especially for patients with complex therapeutic histories.

In May 2022, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare and diagnostics leader, entered into a partnership with The Global Fund to strengthen HIV and tuberculosis diagnostics in low- and middle-income countries (LMICs). The initiative aims to scale up access to diagnostic tools, overcome infrastructure barriers, and promote sustainable healthcare waste management practices. The Global Fund, also based in Switzerland, is a global financing mechanism dedicated to supporting healthcare systems in the fight against HIV/AIDS, tuberculosis, and malaria. This collaboration reflects a broader industry trend of public-private partnerships targeting improved disease detection, early treatment, and pandemic preparedness in underserved regions.

Major players in the human immunodeficiency virus therapeutics market are Pfizer Inc., Johnson & Johnson, F Hoffmann La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol Myers Squibb Company (BMS), Novartis International AG, GlaxoSmithKline plc (GSK), Gilead Sciences Inc., Moderna Inc., BioNTech SE, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Cipla Limited, Hetero Labs Limited, Gilead Sciences Inc. / Kite Pharma Inc. (for CAR T HIV cure research), Vir Biotechnology Inc., Theratechnologies Inc., and CytoDyn Inc.

North America was the largest region in the human immunodeficiency virus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human immunodeficiency virus therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human immunodeficiency virus therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human immunodeficiency virus therapeutics market consists of revenues earned by entities by providing services such as telehealth and remote patient monitoring, patient support and case management services, clinical trials and research services, and HIV testing and diagnosis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The human immunodeficiency virus therapeutics market also includes sales of antiretroviral drugs (ARVs), pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and immune system boosters. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Immunodeficiency Virus Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human immunodeficiency virus therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for human immunodeficiency virus therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human immunodeficiency virus therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Type: Branded Drugs; Generic Drugs
2) By Drug Class: Nucleoside-Analog Reverse Transcriptase Inhibitors (Nrtis); Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis); Entry And Fusion Inhibitors; Protease Inhibitors (Pis); Integrase Inhibitors; Coreceptor Antagonists
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
4) By End-user: Hospitals And Clinics; Specialty Centers
Subsegments:
1) By Branded Drugs: Biktarvy; Triumeq; Genvoya; Juluca; Dovato; Isentress; Prezista
2) By Generic Drugs: Tenofovir Disoproxil Fumarate (TDF); Lamivudine; Efavirenz; Zidovudine; Nevirapine; Abacavir; Ritonavir
Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F Hoffmann La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r34871

1. Executive Summary

2. Human Immunodeficiency Virus Therapeutics Market Characteristics

3. Human Immunodeficiency Virus Therapeutics Market Trends And Strategies

4. Human Immunodeficiency Virus Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Human Immunodeficiency Virus Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Human Immunodeficiency Virus Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Human Immunodeficiency Virus Therapeutics Market Growth Rate Analysis
5.4. Global Human Immunodeficiency Virus Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Human Immunodeficiency Virus Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Human Immunodeficiency Virus Therapeutics Total Addressable Market (TAM)

6. Human Immunodeficiency Virus Therapeutics Market Segmentation

6.1. Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Branded Drugs
Generic Drugs
6.2. Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nucleoside-Analog Reverse Transcriptase Inhibitors (Nrtis)
Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis)
Entry And Fusion Inhibitors
Protease Inhibitors (Pis)
Integrase Inhibitors
Coreceptor Antagonists
6.3. Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
6.4. Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Specialty Centers
6.5. Global Human Immunodeficiency Virus Therapeutics Market, Sub-Segmentation Of Branded Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biktarvy
Triumeq
Genvoya
Juluca
Dovato
Isentress
Prezista
6.6. Global Human Immunodeficiency Virus Therapeutics Market, Sub-Segmentation Of Generic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tenofovir Disoproxil Fumarate (TDF)
Lamivudine
Efavirenz
Zidovudine
Nevirapine
Abacavir
Ritonavir

7. Human Immunodeficiency Virus Therapeutics Market Regional And Country Analysis

7.1. Global Human Immunodeficiency Virus Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Human Immunodeficiency Virus Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market

8.1. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Human Immunodeficiency Virus Therapeutics Market

9.1. China Human Immunodeficiency Virus Therapeutics Market Overview
9.2. China Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Human Immunodeficiency Virus Therapeutics Market

10.1. India Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Human Immunodeficiency Virus Therapeutics Market

11.1. Japan Human Immunodeficiency Virus Therapeutics Market Overview
11.2. Japan Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Human Immunodeficiency Virus Therapeutics Market

12.1. Australia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Human Immunodeficiency Virus Therapeutics Market

13.1. Indonesia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Human Immunodeficiency Virus Therapeutics Market

14.1. South Korea Human Immunodeficiency Virus Therapeutics Market Overview
14.2. South Korea Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Human Immunodeficiency Virus Therapeutics Market

15.1. Western Europe Human Immunodeficiency Virus Therapeutics Market Overview
15.2. Western Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Human Immunodeficiency Virus Therapeutics Market

16.1. UK Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Human Immunodeficiency Virus Therapeutics Market

17.1. Germany Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Human Immunodeficiency Virus Therapeutics Market

18.1. France Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Human Immunodeficiency Virus Therapeutics Market

19.1. Italy Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Human Immunodeficiency Virus Therapeutics Market

20.1. Spain Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Human Immunodeficiency Virus Therapeutics Market

21.1. Eastern Europe Human Immunodeficiency Virus Therapeutics Market Overview
21.2. Eastern Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Human Immunodeficiency Virus Therapeutics Market

22.1. Russia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Human Immunodeficiency Virus Therapeutics Market

23.1. North America Human Immunodeficiency Virus Therapeutics Market Overview
23.2. North America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Human Immunodeficiency Virus Therapeutics Market

24.1. USA Human Immunodeficiency Virus Therapeutics Market Overview
24.2. USA Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Human Immunodeficiency Virus Therapeutics Market

25.1. Canada Human Immunodeficiency Virus Therapeutics Market Overview
25.2. Canada Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Human Immunodeficiency Virus Therapeutics Market

26.1. South America Human Immunodeficiency Virus Therapeutics Market Overview
26.2. South America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Human Immunodeficiency Virus Therapeutics Market

27.1. Brazil Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Human Immunodeficiency Virus Therapeutics Market

28.1. Middle East Human Immunodeficiency Virus Therapeutics Market Overview
28.2. Middle East Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Human Immunodeficiency Virus Therapeutics Market

29.1. Africa Human Immunodeficiency Virus Therapeutics Market Overview
29.2. Africa Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Human Immunodeficiency Virus Therapeutics Market Competitive Landscape And Company Profiles

30.1. Human Immunodeficiency Virus Therapeutics Market Competitive Landscape
30.2. Human Immunodeficiency Virus Therapeutics Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Human Immunodeficiency Virus Therapeutics Market Other Major And Innovative Companies

31.1. Sanofi SA
31.2. Bristol Myers Squibb Company (BMS)
31.3. Novartis International AG
31.4. GlaxoSmithKline plc (GSK)
31.5. Gilead Sciences Inc.
31.6. Moderna Inc.
31.7. BioNTech SE
31.8. Teva Pharmaceutical Industries Ltd.
31.9. Boehringer Ingelheim International GmbH
31.10. Aurobindo Pharma Limited
31.11. Cipla Limited
31.12. Hetero Labs Limited
31.13. Gilead Sciences Inc. / Kite Pharma Inc. (for CAR T HIV cure research)
31.14. Vir Biotechnology Inc.
31.15. Theratechnologies Inc.

32. Global Human Immunodeficiency Virus Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Immunodeficiency Virus Therapeutics Market

34. Recent Developments In The Human Immunodeficiency Virus Therapeutics Market

35. Human Immunodeficiency Virus Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Human Immunodeficiency Virus Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Human Immunodeficiency Virus Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Human Immunodeficiency Virus Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer
250617_r34871_Human_Immunodeficiency_Virus_Therapeutics_GMR_2025